The progress we have made in just the past few months validates our decision to focus on our highest value near-term revenue opportunities. As we've discussed previously, we are primarily focused on ...
PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...
Precigen, Inc. ( PGEN) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Good afternoon, ladies and gentlemen, and welcome to the Precigen Third Quarter 2025 Financial Results and Business Update ...
URochester researchers develop algorithms that reveal how propane becomes propylene for everyday products.Countless everyday products from plastic ...
17 小时on MSN
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III ...
BioAtla’s Q3 2025 update details FDA-aligned Oz-V Phase III trial, peak sales forecast, strategic deal progress, and cost reductions.
Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈